1. Clinical Overview

Molecule: 28-amino acid peptide derived from prothymosin alpha, a thymic precursor central to immune function

Classification: Immune modulator • Anti-inflammatory regulator • T-cell enhancer • Innate immunity stimulant • Anti-viral peptide • Anti-cancer immunotherapeutic

Status: Used in >35 countries. FDA fast-tracked. Approved in several countries for HBV, HCV, immune deficiency. Zadaxin®.

2. Mechanisms of Action

2.1 T-Cell Activation & Differentiation

Enhances CD4+/CD8+ function, improves naive T-cell output, increases cytotoxic T-cell efficiency, restores T-cell balance in immunosuppression/immunosenescence.

2.2 Dendritic Cell Enhancement

Enhanced DC maturation, antigen presentation, coordinated adaptive immunity, improved vaccine responses.

2.3 Th1/Th2 Immune Balance

Restores Th1 dominance in Th2-shifted pathology: viral infections, immunosuppression, cancer immune evasion, chronic fatigue.

2.4 Innate Immunity

NK-cell cytotoxicity, macrophage activation, Toll-like receptor signaling, interferon production. Vital for viral defense.

2.5 Anti-Inflammatory / Immunoregulatory

Reduces cytokine storms, chronic inflammation, autoimmune overactivity, pathologic IL-6/TNF-α. Provides immunobalance, not just stimulation.

2.6 Antiviral & Antimicrobial

Enhanced IFN-α/β signaling: broad antiviral support, viral clearance, reduced persistence. Validated in HBV, HCV, influenza.

3. Clinical Applications

3.1 Immune Restoration & Immunosenescence

Aging adults (>40), frequent infections, poor vaccine response, chronic immune stress.

3.2 Viral Infections

HBV, HCV, influenza, EBV, CMV, HPV, post-viral fatigue, SARS-CoV-2 immune dysfunction.

3.3 Autoimmunity Modulation

Hashimoto’s, RA (supportive), psoriasis, IBD. Immunoregulation, not curative.

3.4 Oncology (Adjunct)

Enhanced chemo/immunotherapy response, NK activity, anti-tumor surveillance, reduced treatment-related suppression. Melanoma, lung, GI, hematologic cancers.

3.5 Sepsis & Critical Illness

Reduced mortality, cytokine dysregulation, organ dysfunction.

3.6 Vaccine Immunopotentiation

Enhanced antibody titers, T-cell response, improved efficacy in elderly/immunocompromised.

3.7 Chronic Inflammatory & Stress

CFS, fibromyalgia (immune component), chronic stress-induced suppression.

4. Administration & Protocols

Standard Immune: 450–900 mcg SC 2–3×/wk × 4–12 weeks
Acute Infection: 1.5–2.0 mg SC daily × 3–7 days → 450–900 mcg 2–3×/wk × 2–4 wk
Autoimmune: 450–900 mcg SC 3×/wk × 6–12+ wk
Oncology: 1.6 mg SC 2–3×/wk alongside treatment
Longevity: 450–750 mcg SC 2×/wk, 8 on / 4 off
Vaccine Enhancement: 450–900 mcg SC 24 hrs before & after vaccination

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ TB-500: Immune repair + tissue repair — chronic inflammatory disease, injury-prone
+ BPC-157: Immune regulation + gut/systemic healing — autoimmune, inflammatory gut
+ NAD+ + SS-31: Immune burnout, mitochondrial dysfunction, aging inflammation
+ MOTS-c: Mitochondrial + immune synergy
+ CJC-1295/Ipamorelin or Sermorelin: GH axis + healing + metabolic resilience
+ KPV: IBD — immune + gut anti-inflammatory pairing

6. Clinical Decision Trees

Tree 1 — Is Tα1 Appropriate?

Recurrent infections? → YES

Chronic viruses (EBV/CMV/HCV/HBV)? → YES

Age/stress immunosuppression? → YES

Oncology immunotherapy support? → YES

Autoimmune dysregulation? → YES (modulatory)

Active cancer? → Oncology guidance only

Pregnancy? → NO

Tree 2 — Dose Selection

Immune optimization → 450–900 mcg 2–3×/wk

Acute infection → 1.5–2 mg daily × 3–7 days

Autoimmune → 450–900 mcg 3×/wk

Oncology → 1.6 mg 2–3×/wk

Longevity → 450–750 mcg 2×/wk

7. Integrated Archetypes

A — Chronic Viral Fatigue / EBV

Tα1 900 mcg SC 3×/wk + NAD+ weekly + Pinealon brain recovery + MOTS-c weekly
Outcome: Improved energy, reduced viral reactivation, restored immunity.

B — Autoimmune Regulation

Tα1 450–900 mcg 3×/wk + KPV daily + BPC-157 gut-immune axis + Omega-3
Outcome: Reduced inflammation, stabilized immune response.

C — Oncology Support (Adjunct)

Tα1 1.6 mg SC 2–3×/wk + DSIP sleep + NAD+ + antioxidant support
Outcome: Improved immune resilience during therapy.

D — Longevity / Immune Optimization

Tα1 750 mcg SC 2×/wk + MOTS-c weekly + GHK-Cu + NAD+ + Mediterranean diet
Outcome: Youthful immune function, reduced inflammation.

8. Expected Timeline

Week 1–2: Improved resilience, reduced fatigue
Week 2–4: Fewer infections, improved energy
Month 2–3: Immune markers stabilize, inflammation decreases
Month 3–6: Long-term immune optimization

9. Contraindications

Absolute

Pregnancy / Breastfeeding
Known hypersensitivity

Relative

Active cancer (oncologist oversight only)
Severe autoimmune flare
Organ transplant (case-by-case)

10. Adverse Effects

Common: Injection-site redness, mild flu-like symptoms, transient fatigue. Less common: Mild GI upset, headache. Rare: Immune overstimulation.

11. Monitoring

CBC with differential
CRP, ESR, cytokine markers
Viral load (if applicable)
Autoimmune markers
Energy/fatigue tracking
IGF-1 if using GH secretagogues

Legal Disclaimer

This document is provided solely for educational and informational purposes. Thymosin Alpha-1 (Tα1 / Thymalfasin) and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Thymosin Alpha-1

Foundational Discovery

1. Goldstein, A. L., et al. Isolation/characterization of Tα1. PNAS, 73(11), 4203–4206 (1976).

2. Garaci, E., et al. Tα1 biology/immunoregulation. Ann NY Acad Sci, 685, 124–134 (1993).

3. Goldstein, A. L. Tα1 biological activities/clinical potential. Cytokine Growth Factor Rev, 8(1), 75–86 (1997).

TLR, Dendritic Cells, T-Cell & NK

4. Romani, L., et al. Tα1 activates DCs via TLRs. Nat Med, 10(12), 151–158 (2004).

5. Pica, F., et al. Th1/IL-12 in dendritic cells. J Immunol, 176(1), 136–142 (2006).

6. King, R., & Tuthill, C. Innate immunity/NK cytotoxicity. Int Immunopharmacol, 6(4), 593–602 (2006).

7. Yamamoto, S., et al. TLR-mediated antiviral responses. J Virol, 82(18), 9235–9245 (2008).

Antiviral — Hepatitis B & C

8. Sherman, K. E., et al. Chronic HBV controlled trial. Hepatology, 23(4), 857–863 (1996).

9. Mutchnick, M. G., et al. Tα1 + IFN for HCV. J Viral Hepat, 16(3), 198–208 (2009).

10. Muthiah, Y. D., et al. Meta-analysis HBV. Aliment Pharmacol Ther, 24(4), 491–500 (2006).

11. Tan, D., et al. Long-term HBV clearance. J Hepatol, 45(2), 196–203 (2006).

Immune Restoration & Vaccine

12. Tuthill, C., & Itri, V. Immunorestorative in secondary deficiency. Int Immunopharmacol, 7(14), 1958–1966 (2007).

13. Fattom, A. I., et al. Vaccine adjuvant T-cell responses. Vaccine, 23(44), 5956–5964 (2005).

14. Garaci, E., et al. Cancer vaccination immunity. Cancer Immunol Immunother, 57(6), 855–864 (2008).

Sepsis & Critical Care

15. Wu, J., et al. Sepsis immune function/survival. Crit Care Med, 42(4), 1044–1052 (2014).

16. Yao, Y. M., et al. Sepsis immunosuppression via TLR9. Shock, 26(6), 643–649 (2006).

17. Li, C., et al. Severe sepsis adjunct. Chin Crit Care Med, 22(5), 258–261 (2010).

COVID-19 & Viral Pneumonia

18. Liu, X., et al. T-cell counts/survival in COVID-19. Int J Infect Dis, 96, 588–593 (2020).

19. Wu, C., et al. Mortality in critical COVID-19. J Med Virol, 93(2), 1117–1125 (2021).

20. Tan, L., et al. Immune competence in viral pneumonia. Front Immunol, 11, 171 (2020).

Oncology

21. Garaci, E., et al. Advanced melanoma adjunct. Cancer Immunol Immunother, 51(1), 49–56 (2002).

22. Adams, G. R., et al. Metastatic melanoma + IFN-α. J Clin Oncol, 19(4), 916–926 (2001).

23. Maio, M., et al. NSCLC + chemo. Lung Cancer, 36(1), 39–45 (2002).

24. Chen, N., et al. CRC immune enhancement. World J Gastroenterol, 11(8), 1151–1155 (2005).

Autoimmune & Anti-Inflammatory

25. Wang, F. S., et al. Cytokines/autoimmune reactivity. Clin Immunol, 105(2), 162–168 (2002).

26. Pica, F., et al. Immune tolerance restoration. Ann NY Acad Sci, 1358(1), 66–77 (2015).

Metabolic & Systemic

27. Pignata, C., et al. Thymus peptides systemic repair. J Endocrinol, 224(1), R1–R12 (2015).

Safety & Regulatory

28. Tuthill, C., et al. Long-term safety/tolerability. Expert Opin Drug Saf, 9(3), 503–511 (2010).

29. FDA CBER. Zadaxin® regulatory/safety. FDA, 2001–2023.

30. EMA. Tα1 risk assessment/pharmacovigilance. EMA, 2005–2023.